WANY
ABBV icon

Wealthspire Advisors (New York)’s AbbVie ABBV Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4M Sell
52,546
-5,888
-10% -$1.31M 0.09% 107
2025
Q4 		$13.4M Buy
58,434
+8,053
+16% +$1.83M 0.11% 93
2025
Q3 		$11.7M Sell
50,381
-473
-0.9% -$96.3K 0.06% 107
2025
Q2 		$9.44M Sell
50,854
-2,888
-5% -$537K 0.05% 122
2025
Q1 		$11.3M Sell
53,742
-1,473
-3% -$286K 0.07% 104
2024
Q4 		$9.81M Sell
55,215
-539
-1% -$99.1K 0.1% 96
2024
Q3 		$11M Buy
55,754
+6,081
+12% +$1.13M 0.11% 93
2024
Q2 		$8.52M Sell
49,673
-3,615
-7% -$599K 0.11% 88
2024
Q1 		$9.7M Sell
53,288
-2,018
-4% -$348K 0.13% 76
2023
Q4 		$8.57M Sell
55,306
-177
-0.3% -$25.8K 0.12% 79
2023
Q3 		$8.27M Buy
55,483
+9,072
+20% +$1.33M 0.14% 77
2023
Q2 		$6.25M Sell
46,411
-551
-1% -$80.8K 0.1% 87
2023
Q1 		$7.48M Sell
46,962
-3,853
-8% -$589K 0.13% 80
2022
Q4 		$8.21M Buy
50,815
+2,578
+5% +$395K 0.15% 79
2022
Q3 		$6.47M Buy
48,237
+446
+0.9% +$64K 0.14% 81
2022
Q2 		$7.32M Buy
47,791
+3,153
+7% +$482K 0.15% 72
2022
Q1 		$7.24M Sell
44,638
-10,433
-19% -$1.52M 0.16% 57
2021
Q4 		$7.46M Buy
55,071
+35,007
+174% +$4.14M 0.17% 60
2021
Q3 		$2.16M Buy
20,064
+10,739
+115% +$1.23M 0.04% 159
2021
Q2 		$1.05M Sell
9,325
-27,263
-75% -$3.07M 0.03% 159
2021
Q1 		$3.96M Buy
36,588
+6,694
+22% +$716K 0.09% 106
2020
Q4 		$3.2M Sell
29,894
-11,565
-28% -$1.11M 0.1% 98
2020
Q3 		$3.63M Buy
41,459
+4,486
+12% +$422K 0.22% 56
2020
Q2 		$3.63M Buy
36,973
+3,980
+12% +$350K 0.25% 48
2020
Q1 		$2.51M Buy
32,993
+23,205
+237% +$1.98M 0.11% 108
2019
Q4 		$867K Buy
9,788
+1,245
+15% +$103K 0.06% 71
2019
Q3 		$647K Buy
8,543
+4,507
+112% +$309K 0.05% 69
2019
Q2 		$293K Buy
+4,036
New +$317K 0.03% 75
2019
Q1 		– Sell
-1,757
Closed -$162K – 50
2018
Q4 		$162K Buy
+1,757
New +$155K 0.02% 77

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealthspire Advisors (New York)'s ABBV Position: Q1 2026 in Review

Wealthspire Advisors (New York) reduced its AbbVie (ABBV) stake by 10% in Q1 2026, selling an estimated $1.31M and leaving 52,546 shares worth $11.4M. The position accounts for 0.09% of the portfolio, ranked #107.

Wealthspire Advisors (New York) first reported a position in ABBV in Q4 2018 and has held it in 29 quarters since. The position peaked at $13.4M in Q4 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Wealthspire Advisors (New York) held 52,546 shares of AbbVie worth $11.4M as of Q1 2026.
  • Wealthspire Advisors (New York) sold 5,888 AbbVie shares in Q1 2026, an estimated $1.31M.
  • AbbVie made up 0.09% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #107 holding.
  • Wealthspire Advisors (New York) first reported a position in AbbVie in Q4 2018 and has held it in 29 quarters since.
  • Wealthspire Advisors (New York)'s AbbVie position peaked at $13.4M in Q4 2025.
  • 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.